Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Recruiting 3Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Breast 2Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 5Endometrial Neoplasms 5Neoplasms 4Head and Neck Neoplasms 3Breast Neoplasms 3Rectal Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Ovarian Carcinosarcoma 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Mouth Neoplasms 1Lung Neoplasms 1Laryngeal Diseases 1Hemangiosarcoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1

Interventions

pembrolizumab 36Bevacizumab 25Cyclophosphamide 23Blood Specimen Collection 19Nivolumab 17Standard of Care 15Carboplatin 15Paclitaxel 14atezolizumab 13Gemcitabine 13Exercise 13Pemetrexed 11Fluorouracil 11Doxorubicin 11Cisplatin 11Cetuximab 10Radiotherapy 9Oxaliplatin 9Magnetic Resonance Spectroscopy 9Leucovorin 9Docetaxel 9130-nm albumin-bound paclitaxel 9durvalumab 8abemaciclib 8Temozolomide 8Surveys and Questionnaires 8Rituximab 8Prednisone 8Biopsy 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neoplasms × dostarlimab × 90 days × Clear all
NCT05277051 2026-05-22

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

GlaxoSmithKline

Phase 1 Active not recruiting
152 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06551142 2026-05-22

PanTumor-101

GlaxoSmithKline

Phase 1 Recruiting
845 enrolled
Tumor-Agnostic

Neoplasms

NCT06796907 2026-05-22

BEHOLD-2

GlaxoSmithKline

Phase 1/2 Recruiting
305 enrolled
Tumor-Agnostic

Neoplasms

NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡